Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189532 | 0.88 | GAA (0.40) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20190841 | 0.87 | GAA (0.39) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20189047 | 0.86 | GPR139 (0.44) | GAAMEN1KMT2APYGL | |
| SCHEMBL20188296 | 0.86 | GAA (0.39) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20188659 | 0.86 | MAPT (0.41) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20187735 | 0.86 | PTPRA (0.40) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20188095 | 0.86 | CA2 (0.36) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20187767 | 0.86 | GAA (0.37) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL22457666 | 0.85 | GAA (0.38) | MAPTCYP1A2CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL20188367 | 0.85 | CA2 (0.39) | CYP1A2CYP2D6SMN1; SMN2GAAPTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | claimed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | MAPT 3724/4885CYP1A2 201/4885CYP2D6 52/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | MAPT 3724/4885CYP1A2 201/4885CYP2D6 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.